Literature DB >> 16210286

How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events?

Nick Freemantle1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16210286      PMCID： PMC1246089          DOI： 10.1136/bmj.331.7520.836

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  3 in total

Review 1.  Interpreting the results of secondary end points and subgroup analyses in clinical trials: should we lock the crazy aunt in the attic?

Authors:  N Freemantle
Journal:  BMJ       Date:  2001-04-21

2.  Composite outcomes in randomized trials: greater precision but with greater uncertainty?

Authors:  Nick Freemantle; Melanie Calvert; John Wood; Joanne Eastaugh; Carl Griffin
Journal:  JAMA       Date:  2003-05-21       Impact factor: 56.272

3.  Carvedilol and the Food and Drug Administration (FDA) approval process: the FDA paradigm and reflections on hypothesis testing.

Authors:  L D Fisher
Journal:  Control Clin Trials       Date:  1999-02
  3 in total
  6 in total

1.  ASCOT: a tale of two treatment regimens: odds are that it's hype.

Authors:  Martin G Duerden
Journal:  BMJ       Date:  2005-10-29

2.  Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: what does evidence from randomised trials show about celecoxib?

Authors:  Jonathan L Underhill
Journal:  BMJ       Date:  2005-12-17

3.  Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial.

Authors:  Z Punthakee; J Bosch; G Dagenais; R Diaz; R Holman; J L Probstfield; A Ramachandran; M C Riddle; L E Rydén; B Zinman; R Afzal; S Yusuf; H C Gerstein
Journal:  Diabetologia       Date:  2011-10-29       Impact factor: 10.122

4.  Midcourse correction to a clinical trial when the event rate is underestimated: the Look AHEAD (Action for Health in Diabetes) Study.

Authors:  Frederick L Brancati; Mary Evans; Curt D Furberg; Nancy Geller; Steven Haffner; Steven E Kahn; Peter G Kaufmann; Cora E Lewis; David M Nathan; Bertram Pitt; Monika M Safford
Journal:  Clin Trials       Date:  2012-02       Impact factor: 2.486

Review 5.  Insulin resistance and the metabolic syndrome--or the pitfalls of epidemiology.

Authors:  J S Yudkin
Journal:  Diabetologia       Date:  2007-06-26       Impact factor: 10.122

Review 6.  Overviews of pathogen emergence: which pathogens emerge, when and why?

Authors:  S Cleaveland; D T Haydon; L Taylor
Journal:  Curr Top Microbiol Immunol       Date:  2007       Impact factor: 4.291
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.